Catalyst
Slingshot members are tracking this event:
Esperion (ESPR) to Announce Clinical Development and Regulatory Plans for Bempedoic Acid + Ezetimibe (BA+EZ) in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2017
Occurred Source:
http://investor.esperion.com/releasedetail.cfm?ReleaseID=1016228
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Clinical Development, Regulatory Plans, Bempedoic Acid, Ezetimibe, Ba, Ez, Ba+ez, Ldl-cholesterol, Cv Risk Reduction
